APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Monoclonal Antibodies Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Therapeutic Monoclonal Antibodies Drug Industry Growth and Trends Forecast to 2032

24 December 2025116 pages

Choose your research edition.

Industry ResearchTherapeutic Monoclonal Antibodies Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Monoclonal Antibodies Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Therapeutic Monoclonal Antibodies Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Monoclonal Antibodies Drug Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Monoclonal Antibodies Drug Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Therapeutic Monoclonal Antibodies Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Therapeutic Monoclonal Antibodies Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Therapeutic Monoclonal Antibodies Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Monoclonal Antibodies Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Therapeutic Monoclonal Antibodies Drug include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck & Co, Novartis and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Therapeutic Monoclonal Antibodies Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Therapeutic Monoclonal Antibodies Drug market size, estimates, and forecasts are presented in terms of sales volume (Tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Therapeutic Monoclonal Antibodies Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Therapeutic Monoclonal Antibodies Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Therapeutic Monoclonal Antibodies Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Therapeutic Monoclonal Antibodies Drug Market by Company

AbbVie

Amgen

AstraZeneca

Bristol-Myers Squibb

Gilead Sciences

Johnson & Johnson

Merck & Co

Novartis

Roche

Innovent

Merck KGaA

Takeda

Seagen

Regeneron

Pfizer

Ono Pharmaceutical

Eli Lilly

Hengrui Medicine

Therapeutic Monoclonal Antibodies Drug Segment by Type

Chimeric Antibodies

Humanized Antibodies

Mouse-derived Antibodies

Therapeutic Monoclonal Antibodies Drug Segment by Application

Immune Diseases

Cancer

Other

Therapeutic Monoclonal Antibodies Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Monoclonal Antibodies Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Monoclonal Antibodies Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Monoclonal Antibodies Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Therapeutic Monoclonal Antibodies Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Therapeutic Monoclonal Antibodies Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Chimeric Antibodies Table 2. Major Company of Humanized Antibodies Table 3. Major Company of Mouse-derived Antibodies Table 4. Global Therapeutic Monoclonal Antibodies Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 6. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Type (2021-2026) Table 7. Global Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (US$ Million) Table 8. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Type (2021-2026) Table 9. Global Therapeutic Monoclonal Antibodies Drug Price by Type (2021-2026) & (US$/Ton) Table 10. Global Therapeutic Monoclonal Antibodies Drug Sales by Type (2027-2032) & (Tons) Table 11. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Type (2027-2032) Table 12. Global Therapeutic Monoclonal Antibodies Drug Sales by Type (2027-2032) & (US$ Million) Table 13. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Type (2027-2032) Table 14. Global Therapeutic Monoclonal Antibodies Drug Price by Type (2027-2032) & (US$/Ton) Table 15. North America Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 16. North America Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 18. Europe Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 20. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 22. Latin America Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 24. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Therapeutic Monoclonal Antibodies Drug Industry Trends Table 26. Therapeutic Monoclonal Antibodies Drug Industry Drivers Table 27. Therapeutic Monoclonal Antibodies Drug Industry Opportunities and Challenges Table 28. Therapeutic Monoclonal Antibodies Drug Industry Restraints Table 29. Global Therapeutic Monoclonal Antibodies Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Company (2021-2026) Table 31. Global Therapeutic Monoclonal Antibodies Drug Sales by Company (2021-2026) & (Tons) Table 32. Global Therapeutic Monoclonal Antibodies Drug Sales Share by Company (2021-2026) Table 33. Global Therapeutic Monoclonal Antibodies Drug Market Price by Company (2021-2026) & (US$/Ton) Table 34. Global Therapeutic Monoclonal Antibodies Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Therapeutic Monoclonal Antibodies Drug Major Company Production Sites and Headquarters Table 36. Global Therapeutic Monoclonal Antibodies Drug Company, Product Type & Application Table 37. Global Therapeutic Monoclonal Antibodies Drug Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Therapeutic Monoclonal Antibodies Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Therapeutic Monoclonal Antibodies Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2021-2026) & (Tons) Table 42. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Region (2021-2026) Table 43. Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2021-2026) & (US$ Million) Table 44. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Region (2021-2026) Table 45. Global Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 46. Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2027-2032) & (Tons) Table 47. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Region (2027-2032) Table 48. Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2027-2032) & (US$ Million) Table 49. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Region (2027-2032) Table 50. Global Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2027-2032) Table 51. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 53. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Application (2021-2026) Table 54. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (US$ Million) Table 55. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Application (2021-2026) Table 56. Global Therapeutic Monoclonal Antibodies Drug Price by Application (2021-2026) & (US$/Ton) Table 57. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2027-2032) & (Tons) Table 58. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Application (2027-2032) Table 59. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2027-2032) & (US$ Million) Table 60. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Application (2027-2032) Table 61. Global Therapeutic Monoclonal Antibodies Drug Price by Application (2027-2032) & (US$/Ton) Table 62. North America Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 63. North America Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 65. Europe Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 67. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 69. Latin America Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 71. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (US$ Million) Table 72. AbbVie Company Information Table 73. AbbVie Business Overview Table 74. AbbVie Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 75. AbbVie Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 76. AbbVie Recent Development Table 77. Amgen Company Information Table 78. Amgen Business Overview Table 79. Amgen Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 80. Amgen Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 81. Amgen Recent Development Table 82. AstraZeneca Company Information Table 83. AstraZeneca Business Overview Table 84. AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 85. AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 86. AstraZeneca Recent Development Table 87. Bristol-Myers Squibb Company Information Table 88. Bristol-Myers Squibb Business Overview Table 89. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 90. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 91. Bristol-Myers Squibb Recent Development Table 92. Gilead Sciences Company Information Table 93. Gilead Sciences Business Overview Table 94. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 95. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 96. Gilead Sciences Recent Development Table 97. Johnson & Johnson Company Information Table 98. Johnson & Johnson Business Overview Table 99. Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 100. Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 101. Johnson & Johnson Recent Development Table 102. Merck & Co Company Information Table 103. Merck & Co Business Overview Table 104. Merck & Co Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 105. Merck & Co Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 106. Merck & Co Recent Development Table 107. Novartis Company Information Table 108. Novartis Business Overview Table 109. Novartis Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 110. Novartis Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 111. Novartis Recent Development Table 112. Roche Company Information Table 113. Roche Business Overview Table 114. Roche Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 115. Roche Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 116. Roche Recent Development Table 117. Innovent Company Information Table 118. Innovent Business Overview Table 119. Innovent Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 120. Innovent Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 121. Innovent Recent Development Table 122. Merck KGaA Company Information Table 123. Merck KGaA Business Overview Table 124. Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 125. Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 126. Merck KGaA Recent Development Table 127. Takeda Company Information Table 128. Takeda Business Overview Table 129. Takeda Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 130. Takeda Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 131. Takeda Recent Development Table 132. Seagen Company Information Table 133. Seagen Business Overview Table 134. Seagen Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 135. Seagen Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 136. Seagen Recent Development Table 137. Regeneron Company Information Table 138. Regeneron Business Overview Table 139. Regeneron Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 140. Regeneron Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 141. Regeneron Recent Development Table 142. Pfizer Company Information Table 143. Pfizer Business Overview Table 144. Pfizer Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 145. Pfizer Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 146. Pfizer Recent Development Table 147. Ono Pharmaceutical Company Information Table 148. Ono Pharmaceutical Business Overview Table 149. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 150. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 151. Ono Pharmaceutical Recent Development Table 152. Eli Lilly Company Information Table 153. Eli Lilly Business Overview Table 154. Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 155. Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 156. Eli Lilly Recent Development Table 157. Hengrui Medicine Company Information Table 158. Hengrui Medicine Business Overview Table 159. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 160. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 161. Hengrui Medicine Recent Development Table 162. North America Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 163. North America Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons) Table 164. North America Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country (2021-2026) Table 165. North America Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032) & (Tons) Table 166. North America Therapeutic Monoclonal Antibodies Drug Sales Market Share Forecast by Country (2027-2032) Table 167. North America Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. North America Therapeutic Monoclonal Antibodies Drug Market Size by Country (2021-2026) & (US$ Million) Table 169. North America Therapeutic Monoclonal Antibodies Drug Market Share by Country (2021-2026) Table 170. North America Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. North America Therapeutic Monoclonal Antibodies Drug Market Share Forecast by Country (2027-2032) Table 172. Europe Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 173. Europe Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons) Table 174. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country (2021-2026) Table 175. Europe Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032) & (Tons) Table 176. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share Forecast by Country (2027-2032) Table 177. Europe Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 178. Europe Therapeutic Monoclonal Antibodies Drug Market Size by Country (2021-2026) & (US$ Million) Table 179. Europe Therapeutic Monoclonal Antibodies Drug Market Share by Country (2021-2026) Table 180. Europe Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 181. Europe Therapeutic Monoclonal Antibodies Drug Market Share Forecast by Country (2027-2032) Table 182. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 183. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons) Table 184. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country (2021-2026) Table 185. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032) & (Tons) Table 186. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Market Share Forecast by Country (2027-2032) Table 187. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 188. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Size by Country (2021-2026) & (US$ Million) Table 189. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Share by Country (2021-2026) Table 190. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 191. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Share Forecast by Country (2027-2032) Table 192. Latin America Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 193. Latin America Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons) Table 194. Latin America Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country (2021-2026) Table 195. Latin America Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032) & (Tons) Table 196. Latin America Therapeutic Monoclonal Antibodies Drug Sales Market Share Forecast by Country (2027-2032) Table 197. Latin America Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 198. Latin America Therapeutic Monoclonal Antibodies Drug Market Size by Country (2021-2026) & (US$ Million) Table 199. Latin America Therapeutic Monoclonal Antibodies Drug Market Share by Country (2021-2026) Table 200. Latin America Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 201. Latin America Therapeutic Monoclonal Antibodies Drug Market Share Forecast by Country (2027-2032) Table 202. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 203. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons) Table 204. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country (2021-2026) Table 205. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032) & (Tons) Table 206. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share Forecast by Country (2027-2032) Table 207. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 208. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size by Country (2021-2026) & (US$ Million) Table 209. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Share by Country (2021-2026) Table 210. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 211. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Share Forecast by Country (2027-2032) Table 212. Key Raw Materials Table 213. Raw Materials Key Suppliers Table 214. Therapeutic Monoclonal Antibodies Drug Distributors List Table 215. Therapeutic Monoclonal Antibodies Drug Customers List Table 216. Research Programs/Design for This Report Table 217. Authors List of This Report Table 218. Secondary Sources Table 219. Primary Sources List of Figures Figure 1. Therapeutic Monoclonal Antibodies Drug Image Figure 2. Global Therapeutic Monoclonal Antibodies Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Monoclonal Antibodies Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Monoclonal Antibodies Drug Sales (2021-2032) & (Tons) Figure 5. Chimeric Antibodies Image Figure 6. Global Chimeric Antibodies Sales YoY Growth (2021-2032) & (Tons) Figure 7. Humanized Antibodies Image Figure 8. Global Humanized Antibodies Sales YoY Growth (2021-2032) & (Tons) Figure 9. Mouse-derived Antibodies Image Figure 10. Global Mouse-derived Antibodies Sales YoY Growth (2021-2032) & (Tons) Figure 11. Global Therapeutic Monoclonal Antibodies Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Therapeutic Monoclonal Antibodies Drug Market Share by Type 2025 VS 2032 Figure 13. North America Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Type in 2025 Figure 14. North America Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Type in 2025 Figure 15. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Type in 2025 Figure 16. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Type in 2025 Figure 19. Latin America Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Therapeutic Monoclonal Antibodies Drug Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Immune Diseases Image Figure 26. Global Immune Diseases Sales YoY Growth (2021-2032) & (Tons) Figure 27. Cancer Image Figure 28. Global Cancer Sales YoY Growth (2021-2032) & (Tons) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (Tons) Figure 31. Global Therapeutic Monoclonal Antibodies Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Therapeutic Monoclonal Antibodies Drug Market Share by Application 2025 VS 2032 Figure 33. North America Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Application in 2025 Figure 34. North America Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Application in 2025 Figure 35. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Application in 2025 Figure 36. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Application in 2025 Figure 39. Latin America Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share in Value by Application in 2025 Figure 43. North America Therapeutic Monoclonal Antibodies Drug Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 44. North America Therapeutic Monoclonal Antibodies Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Therapeutic Monoclonal Antibodies Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Therapeutic Monoclonal Antibodies Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Therapeutic Monoclonal Antibodies Drug Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 48. Europe Therapeutic Monoclonal Antibodies Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Therapeutic Monoclonal Antibodies Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Therapeutic Monoclonal Antibodies Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 52. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Therapeutic Monoclonal Antibodies Drug Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 56. Latin America Therapeutic Monoclonal Antibodies Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Therapeutic Monoclonal Antibodies Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Therapeutic Monoclonal Antibodies Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 60. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Therapeutic Monoclonal Antibodies Drug Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Therapeutic Monoclonal Antibodies Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Chimeric Antibodies
  • Humanized Antibodies
  • Mouse-derived Antibodies
Applications
  • Immune Diseases
  • Cancer
  • Other
Companies covered
  • AbbVie
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Johnson & Johnson
  • Merck & Co
  • Novartis
  • Roche
  • Innovent
  • Merck KGaA
  • Takeda
  • Seagen
  • Regeneron
  • Pfizer
  • Ono Pharmaceutical
  • Eli Lilly
  • Hengrui Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Therapeutic Monoclonal Antibodies Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Therapeutic Monoclonal Antibodies Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Therapeutic Monoclonal Antibodies Drug Market by Type
  6. 1.3.1 Chimeric Antibodies
  7. 1.3.2 Humanized Antibodies
  8. 1.3.3 Mouse-derived Antibodies
  9. 1.4 Global Therapeutic Monoclonal Antibodies Drug Market Size by Type
  10. 1.4.1 Global Therapeutic Monoclonal Antibodies Drug Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Therapeutic Monoclonal Antibodies Drug Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Therapeutic Monoclonal Antibodies Drug Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Therapeutic Monoclonal Antibodies Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Therapeutic Monoclonal Antibodies Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Therapeutic Monoclonal Antibodies Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Therapeutic Monoclonal Antibodies Drug Industry Trends
  2. 2.2 Therapeutic Monoclonal Antibodies Drug Industry Drivers
  3. 2.3 Therapeutic Monoclonal Antibodies Drug Industry Opportunities and Challenges
  4. 2.4 Therapeutic Monoclonal Antibodies Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Therapeutic Monoclonal Antibodies Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Therapeutic Monoclonal Antibodies Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Therapeutic Monoclonal Antibodies Drug Price (2021-2026)
  4. 3.4 Global Therapeutic Monoclonal Antibodies Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Therapeutic Monoclonal Antibodies Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Therapeutic Monoclonal Antibodies Drug Company, Product Type & Application
  7. 3.7 Global Therapeutic Monoclonal Antibodies Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Therapeutic Monoclonal Antibodies Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Therapeutic Monoclonal Antibodies Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Therapeutic Monoclonal Antibodies Drug Tier 1, Tier 2, and Tier 3
4 Therapeutic Monoclonal Antibodies Drug Regional Status and Outlook
  1. 4.1 Global Therapeutic Monoclonal Antibodies Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Therapeutic Monoclonal Antibodies Drug Historic Market Size by Region
  3. 4.2.1 Global Therapeutic Monoclonal Antibodies Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Therapeutic Monoclonal Antibodies Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Therapeutic Monoclonal Antibodies Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Therapeutic Monoclonal Antibodies Drug Forecasted Market Size by Region
  7. 4.3.1 Global Therapeutic Monoclonal Antibodies Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Therapeutic Monoclonal Antibodies Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Therapeutic Monoclonal Antibodies Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Therapeutic Monoclonal Antibodies Drug by Application
  1. 5.1 Therapeutic Monoclonal Antibodies Drug Market by Application
  2. 5.1.1 Immune Diseases
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global Therapeutic Monoclonal Antibodies Drug Market Size by Application
  6. 5.2.1 Global Therapeutic Monoclonal Antibodies Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Therapeutic Monoclonal Antibodies Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Therapeutic Monoclonal Antibodies Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Therapeutic Monoclonal Antibodies Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Therapeutic Monoclonal Antibodies Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Therapeutic Monoclonal Antibodies Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AbbVie
  2. 6.1.1 AbbVie Company Information
  3. 6.1.2 AbbVie Business Overview
  4. 6.1.3 AbbVie Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AbbVie Therapeutic Monoclonal Antibodies Drug Product Portfolio
  6. 6.1.5 AbbVie Recent Developments
  7. 6.2 Amgen
  8. 6.2.1 Amgen Company Information
  9. 6.2.2 Amgen Business Overview
  10. 6.2.3 Amgen Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Amgen Therapeutic Monoclonal Antibodies Drug Product Portfolio
  12. 6.2.5 Amgen Recent Developments
  13. 6.3 AstraZeneca
  14. 6.3.1 AstraZeneca Company Information
  15. 6.3.2 AstraZeneca Business Overview
  16. 6.3.3 AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Portfolio
  18. 6.3.5 AstraZeneca Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 Gilead Sciences
  26. 6.5.1 Gilead Sciences Company Information
  27. 6.5.2 Gilead Sciences Business Overview
  28. 6.5.3 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Portfolio
  30. 6.5.5 Gilead Sciences Recent Developments
  31. 6.6 Johnson & Johnson
  32. 6.6.1 Johnson & Johnson Company Information
  33. 6.6.2 Johnson & Johnson Business Overview
  34. 6.6.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Product Portfolio
  36. 6.6.5 Johnson & Johnson Recent Developments
  37. 6.7 Merck & Co
  38. 6.7.1 Merck & Co Company Information
  39. 6.7.2 Merck & Co Business Overview
  40. 6.7.3 Merck & Co Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Merck & Co Therapeutic Monoclonal Antibodies Drug Product Portfolio
  42. 6.7.5 Merck & Co Recent Developments
  43. 6.8 Novartis
  44. 6.8.1 Novartis Company Information
  45. 6.8.2 Novartis Business Overview
  46. 6.8.3 Novartis Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Novartis Therapeutic Monoclonal Antibodies Drug Product Portfolio
  48. 6.8.5 Novartis Recent Developments
  49. 6.9 Roche
  50. 6.9.1 Roche Company Information
  51. 6.9.2 Roche Business Overview
  52. 6.9.3 Roche Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Roche Therapeutic Monoclonal Antibodies Drug Product Portfolio
  54. 6.9.5 Roche Recent Developments
  55. 6.10 Innovent
  56. 6.10.1 Innovent Company Information
  57. 6.10.2 Innovent Business Overview
  58. 6.10.3 Innovent Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Innovent Therapeutic Monoclonal Antibodies Drug Product Portfolio
  60. 6.10.5 Innovent Recent Developments
  61. 6.11 Merck KGaA
  62. 6.11.1 Merck KGaA Company Information
  63. 6.11.2 Merck KGaA Business Overview
  64. 6.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Portfolio
  66. 6.11.5 Merck KGaA Recent Developments
  67. 6.12 Takeda
  68. 6.12.1 Takeda Company Information
  69. 6.12.2 Takeda Business Overview
  70. 6.12.3 Takeda Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Takeda Therapeutic Monoclonal Antibodies Drug Product Portfolio
  72. 6.12.5 Takeda Recent Developments
  73. 6.13 Seagen
  74. 6.13.1 Seagen Company Information
  75. 6.13.2 Seagen Business Overview
  76. 6.13.3 Seagen Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Seagen Therapeutic Monoclonal Antibodies Drug Product Portfolio
  78. 6.13.5 Seagen Recent Developments
  79. 6.14 Regeneron
  80. 6.14.1 Regeneron Company Information
  81. 6.14.2 Regeneron Business Overview
  82. 6.14.3 Regeneron Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Regeneron Therapeutic Monoclonal Antibodies Drug Product Portfolio
  84. 6.14.5 Regeneron Recent Developments
  85. 6.15 Pfizer
  86. 6.15.1 Pfizer Company Information
  87. 6.15.2 Pfizer Business Overview
  88. 6.15.3 Pfizer Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Pfizer Therapeutic Monoclonal Antibodies Drug Product Portfolio
  90. 6.15.5 Pfizer Recent Developments
  91. 6.16 Ono Pharmaceutical
  92. 6.16.1 Ono Pharmaceutical Company Information
  93. 6.16.2 Ono Pharmaceutical Business Overview
  94. 6.16.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Portfolio
  96. 6.16.5 Ono Pharmaceutical Recent Developments
  97. 6.17 Eli Lilly
  98. 6.17.1 Eli Lilly Company Information
  99. 6.17.2 Eli Lilly Business Overview
  100. 6.17.3 Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Portfolio
  102. 6.17.5 Eli Lilly Recent Developments
  103. 6.18 Hengrui Medicine
  104. 6.18.1 Hengrui Medicine Company Information
  105. 6.18.2 Hengrui Medicine Business Overview
  106. 6.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Portfolio
  108. 6.18.5 Hengrui Medicine Recent Developments
7 North America by Country
  1. 7.1 North America Therapeutic Monoclonal Antibodies Drug Sales by Country
  2. 7.1.1 North America Therapeutic Monoclonal Antibodies Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Therapeutic Monoclonal Antibodies Drug Market Size by Country
  6. 7.2.1 North America Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Therapeutic Monoclonal Antibodies Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Therapeutic Monoclonal Antibodies Drug Sales by Country
  2. 8.1.1 Europe Therapeutic Monoclonal Antibodies Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Therapeutic Monoclonal Antibodies Drug Market Size by Country
  6. 8.2.1 Europe Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Therapeutic Monoclonal Antibodies Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales by Country
  2. 9.1.1 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Therapeutic Monoclonal Antibodies Drug Sales by Country
  2. 10.1.1 South America Therapeutic Monoclonal Antibodies Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Therapeutic Monoclonal Antibodies Drug Market Size by Country
  6. 10.2.1 South America Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Therapeutic Monoclonal Antibodies Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Country
  2. 11.1.1 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Therapeutic Monoclonal Antibodies Drug Value Chain Analysis
  2. 12.1.1 Therapeutic Monoclonal Antibodies Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Therapeutic Monoclonal Antibodies Drug Production Mode & Process
  7. 12.2 Therapeutic Monoclonal Antibodies Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Therapeutic Monoclonal Antibodies Drug Distributors
  10. 12.2.3 Therapeutic Monoclonal Antibodies Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst